(Reuters) – Bristol-Myers Squibb Co said on Monday it would divest Celgene Corp’s psoriasis treatment Otezla as the companies look to gain approval for their $74 billion deal from the U.S. Federal Trade Commission (FTC).
Bristol announced its plans to buy Celgene in a cash-and-stock deal in early January to bring together the companies that specialize in oncology and cardiovascular drugs in the largest pharmaceutical industry merger ever.
March - FTC - Information - Companies - Psoriasis
In March, the FTC had sought additional information from the companies as it focused on their psoriasis treatments as part of its review of their planned merger.
Otezla brought in revenue...
Wake Up To Breaking News!
Would you let a person who could only get a government job run your life? Well don't!